[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 423
Citations 0
November 2016

Error in Graph Line Labels

JAMA Intern Med. 2016;176(11):1729. doi:10.1001/jamainternmed.2016.7319

In the Original Investigation by Graham et al titled “Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation,” published online October 3, 2016, in JAMA Internal Medicine,1 the graph lines in Figure 1, panels B, C, and D, were mislabeled. In all graphs, the blue lines correctly indicate rivaroxaban, and the black lines correctly indicate dabigatran. This article was corrected online.

Graham  DJ, Reichman  ME, Wernecke  M,  et al.  Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation  [published online October 3, 2016]. JAMA Intern Med. doi:10.1001/jamainternmed.2016.5954